Non-4RT FTLD comprised 46 patients with TAR DNA-binding protein 43 (TDP-43) pathology, 10 patients with three-repeat (3R)-tau pathology (Pick’s disease), and four patients with fused in sarcoma (FUS) protein pathology. This evidence concerns the gene FUS and Pick disease.